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Objective: To assess the safety and efﬁcacy of the GenousTM endothelial progenitor cell (EPC) capturing
stent in conjunction with HmG-CoA-reductase inhibitors (statins) to stimulate EPC recruitment, in the
treatment of patients with de novo coronary artery lesions.
Methods and results: The HEALING IIB study was a multi-center, prospective trial, including 100 patients.
The primary efﬁcacy endpoint was late luminal loss by QCA at 6-month follow-up (FU). Although statin
therapy increased relative EPC levels by 5.6-fold, the angiographic outcome at 6 month FU was not
improved in patients with an overall in-stent late luminal loss of 0.76±0.50mm. The composite major
adverse cardiac events (MACE) rate was 9.4%, whereas 6.3% clinically justiﬁed target lesion revascular-
izations (TLRs) were observed. 2 Patients died within the ﬁrst 30 days after stent implantation due to
angiographically veriﬁed in-stent thrombosis. At 12 month FU, MACE and TLR increased to 15.6% and
11.5% respectively and stabilized until 24 month FU. 18 Month angiographic FU showed a signiﬁcanteo-intima hyperplasia decrease in late luminal loss (0.67±0.54, 11.8% reduction or 10% by matched serial analysis, P=0.001).
Conclusion: TheHEALING IIB study suggests that statin therapy in combinationwith the EPC capture stent
does not contribute to a reduction of in-stent restenosis formation for the treatment of de novo coronary
artery disease. Although concomitant statin therapy was able to stimulate EPC recruitment, it did not
improve the angiographic outcome of the bio-engineered EPC capture stent. Remarkably, angiographic
late loss was signiﬁcantly redu
 Independent Imaging Core lab (QCA/QCU) and data monitoring by Cardialysis
v, Rotterdam, The Netherlands.
 ClinicalTrial.gov number NCT00349895.
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1. Introduction
Drug eluting stents (DES) have emerged as an effective means
of attenuating stent-related restenosis formation and has enabled
Open access under the Elsevier OA license.the ﬁeld of percutanuous coronary intervention to move forward
to complex coronary angioplasty, with an efﬁcacy equivalent to
surgical intervention in the short and long term [1]. The main-
stay of drugs eluted from the stent polymer comprise cytostatic
2 erosclerosis 219 (2011) 245–252
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Table 1
Patient demographics and clinical characteristics.
Patient parameter HEALING II (n=63) HEALING IIB (n=96)
Age (years)
Mean SD 60.8±10.2 63.7±9.8
Min–max 43–78 43–78
Body mass index (kg/m2)
Mean SD 26.8±3.7 27.3±4.5
Min–max 18.7–38.1 17.1–41.9
Male 66.7% (42/63) 73.7% (71/96)
Diabetes mellitus 12.7% (8/63) 19.8% (19/96)
Hypertension 46.0% (29/63) 66.7% 64/96)a
Hypercholesterolemia 66.7% (42/63) 84.4% 81/96)a
Previous stroke 3.2% (2/63) 3.1% (3/96)
Congestive heart failure 0.0% (0/63) 3.0% (3/96)
Family history of MI 52.4% (33/63) 55.2% 53/96)
Peripheral vascular disease 3.2% (2/63) 9.4% (9/96)
Previous MI 23.8% (15/63) 26% (25/96)
Previous CABG 3.2% (2/63) 2.01 (2/96)
Previous PTCA 9.5% (6/63) 18.8% (18/96)
Smoking history
Previous 2.2% (14/63) 42.7% (41/96)b
Current 41.3% (26/63) 20.8% (20/96)b
Unstable angina 27.0% (17/63) 8.3% (8/96)b
Braunwald I 9.5% (6/63) 1.0% (1/96)
Braunwald II 1.2% (8/63) 5.2% (5/96)
Braunwald III 4.8% (3/63) 2.1% (2/96)
Stable angina 60.3% (38/63) 80.2% (77/96)b
CCS I 7.9% (5/63) 11.5% (11/96)
CCS II 28.6% 18/63) 56.3% (54/96)
CCS III 20.6% (13/63) 10.4% (10/96)
CCS IV 3.2% (2/63) 2.1% (2/96)
Silent ischemia 12.7% (8/63) 11.5% (11/96)
Numbers are % (counts/available ﬁeld sample size) or mean±1 standard deviation.
SD, standard deviation; MI, myocardial infarction; CABG, coronary artery bypass
graft; PTCA, percutaneous transluminal coronary angioplasty; Braunwald, Braun-46 W.K. den Dekker et al. / Ath
r cytotoxic compounds to impede neointimal formation that
rise from vascular smooth muscle cell (VSMC) activation and
roliferation. Lately, DES have been associated with late in-stent
hrombosis, presumably based on a concomitant impeded arterial
epair response characterized by incomplete endothelial coverage
f the stent struts, persistent ﬁbrin deposition and inﬂamma-
ion beyond 24-month post implantation [2]. Therefore, prolonged
6–12 months) dual anti-platelet therapy has been recommended
n conjunctionwithDES in order tomitigate the risk of stent throm-
osis that is associated with incomplete healing. In addition, the
olymer coating of the DES, which ensures prolonged release of
he anti-proliferative compounds, inherently invokes inﬂamma-
ion and cytotoxicity with delayed stent coverage. Furthermore,
on-erodable polymers were associated with granulomatous and
ypersensitivity reactions in relevant animal models. Finally, DES
ave been shown to interfere with proper endothelial function in
rterial segments adjacent to the implanted stent, as suggested by
n impaired or paradoxical vasomotor response, which could pose
he segment at risk for ischemia and coronary occlusion [3].
Alternatively, therapeutic interventions aimed to facilitate the
ascular repair response following coronary intervention could
einstate endothelial integrity and maintain vascular senescence
o prevent VSMC proliferation, local inﬂammation and vascular
latelet activation, while maintaining local vasomotor function to
nsure short and long-term success of the treated arterial segment.
he underlying strategy of accelerated endothelialization aims to
rovide a non-thrombogenic coating of exposed stent surfaces to
educe in-stent thrombosis and potentially decrease neointimal
yperplasia. Reinstatement of the endothelial integrity can be aug-
ented by local delivery of endothelial mitogenic compounds,
ncluding VEGF [4], or facilitation of attachment of circulating
ndothelial progenitor cells (EPCs) to the strut surface.
In 2003, developmentwas begun of a bio-engineered stent with
proprietary coating containing an anti-human CD34 antibody
GenousTM Bio-engineered R stent, OrbusNeich) that sequesters
irculating CD34+ haematopoietic cells to the stent strut surface,
acilitates strut coverage and initiates the arterial repair response.
oreover, the combination of this CD34 antibody-coating with
onventional sirolimus-eluting stents appeared to overcome the
elayed endothelial coverage in stented porcine coronary arteries
5].
Theﬁrst clinical experiencewith theEPCcapturingGenousStent
as obtained in 16 patients in the HEALING-FIM study. The healing
echnology approachwasdeemed safe and feasiblewith an in-stent
ate luminal loss of 0.63±0.21mm at the 6 month angiographic
ollow-up (FU) [6]. The original design of this stent platform was
dapted before proceeding to the phase I/II study, including modi-
cation of monoclonal antibody with a higher afﬁnity and transfer
rom a wet to a dry lyophilized preparation CD34-antibody coated
tent premounted on anEvolution2TM PTCAballoon catheter. In the
EALING II study, treatment with the Genous Stent of 63 elective
atients with a de-novo lesion resulted in a 6-month angiographic
ate loss of 0.78±0.39mm and percent in-stent volume obstruc-
ion of 22.9±13.7% [7,8]. A sub-analysis of the individual patients
uggested that speciﬁcally patients with a EPC titer responded rel-
tively poorly to the EPC capture technology compared to patients
ith a normal low EPC titer, with more prominent late loss and
igher incidence of revascularization events. Low EPC titer con-
urredwith a lack of HMG-CoA-reductase inhibitors (statins) in the
harmacotherapy of these CAD patients.
As statins have been shown to augment EPC titer, survival, and
ctivity in vitro and in vivo, we hypothesized that concomitant
reatment of CAD with statin therapy could stimulate the EPC titer
nd efﬁcacy in these patients and therefore the overall response to
he EPC capture technology. This led to the design of the HEALING
IB study that aimed to assess the safety and efﬁcacy of the Genouswald classiﬁcation; CCS, Canadian Cardiovascular Society Classiﬁcation.
a P<0.05
b P<0.01
Stent in conjunction with optimal statin therapy to stimulate EPC
recruitment in the treatment of stent-related restenosis formation
in 100 elective patientswith denovonative coronary artery lesions.
2. Methods
For full description of the methods, an expanded “Methods”
section is available in the On-line Data Supplement.
3. Results
3.1. Baseline characteristics and procedural outcome
One hundred patients were included in the HEALING IIB study.
Four patients were per protocol excluded from post-procedural
analysis; two patients did not meet the in- and exclusion criteria,
one patient was not on Atorvastatin during 2 weeks pre-procedure
as required per protocol and one patient had a post-procedural
diameter stenosis of 32% despite post dilatation (see Fig. 1 for ﬂow
chart). The baseline patient demographics, lesion characteristics
and clinical outcomes of the current HEALING IIB and earlier HEAL-
ING II study are summarized in Tables 1–3. The study population
had an average age of 64 years, whereas 20% of the patients suf-
fered from diabetes mellitus. Compared to the HEALING II study,
patients in the HEALING IIB study had signiﬁcantlymore hyperten-
sion, hypercholesterolemia and stable angina and there weremore
current smokers. On the other hand, there were signiﬁcantly less
previous smokers and patients with unstable angina. At the index
procedure, 100% of the patients were initiated on high dose Ator-
vastatin therapy (80mgqd) for at least 2 weeks according to the
protocol outline. At one month FU, 91% of the patients were still
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eing treatedwith Atorvastatin 80mgqd. In 82 patients, one single
ndex lesionwas treated,whereas in 14patients, 2 lesions in 2 inde-
endent coronary arteries received a study stent (total 110 lesions
reated). The average lesion length comprised 12.64±5.69mm in
ength, with a diameter stenosis of 57.9±9.9%, as assessed by QCA.
ngiographic and overall procedural success were respectively
7.3% (107 out of 110 lesions treated) and 93% (89/96 patients;
able 4). A second overlapping EPC capture stent was implanted in
hree patients to treat a dissection following implantation of the
rst stent type (A/B dissection), and in eight patients due to incom-
lete coverage of the target lesion by the ﬁrst stent. Two patients
isplayed a transient TIMI II coronary ﬂow following stent deploy-t and follow-up of 100 patients.
ment. None of the patients received GPIIb/IIIa inhibitors during or
after the index procedure.
3.2. Clinical outcomes
Compliance to clinical FU at 6, 12 and 24 months was 96%, 96%
and 95% respectively. Table 3 provides an overview of the major
adverse cardiac events (MACE) at 1, 6, 12, 18 and 24 months. Clini-
cal outcomes were comparable with the HEALING II study, as there
was only a signiﬁcant difference in TVR at 18 months. Acute in-
stent thrombosis was veriﬁed in two patients within the 30 days
FU. One patient suffered from an angiographically veriﬁed in-stent
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Table 2
Lesion characteristics.
Parameter HEALING II HEALING IIB
# SD or % # SD or %
Study stents per patient 1.1 0.4 1.3 0.5b
Treated segments 63 110
RCA 24 38.1% 40 36.5%
LM 0 0.0% 0 0.0%
LAD 25 39.7% 43 39.1%
LCX 14 22.2% 27 24.5%
Total stent length [mm] 17.0 2.9 21.4 8.5b
Lesion typea 63 107
A 0 0.0% 1 0.9%
B1 27 42.9% 49 45.8%
B2 36 57.2% 53 49.5%
C 0 0.0% 4 3.7%
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hAD, left anterior descending; LCX, left circumﬂex artery; LM, left main; RCA, right
a According to ACC/AHA classiﬁcation.
b P<0.0001.
hrombosis at day one post-implantation and died. Another patient
uffered from an angiographically veriﬁed acute in-stent thrombo-
is at day 9 post-implantation and the patient died. This patient
eceived stents in a bifurcation with residual dissection following
tent implantation, whereas a second stent could not be implanted.
he procedure was assumed not to be a procedural success with
uboptimal stent implantation. Both of these events have been
djudicated as cardiac deaths due to a deﬁnite in-stent thrombosis
y the independent CEC. Finally, one patient had a clinically driven
arget lesion revascularization (TLR) at181days following the index
rocedure, and 4 days after the re-intervention due to a clinically
riven TLR, designated as a secondary, deﬁnite in-stent thrombosis.
uring the re-intervention, the interventionist reported a left main
issection and thrombus in situ in the LAD and left circumﬂexwith
ormal coronary ﬂow.
Clinically driven TLR by repeat PCI occurred in 6.3% at 6 month
U and increased to 9.4% at 12 month FU. After 12 month FU, no
urther TLRs were reported and the TLR rate remained stable at
.4%. Total MACE rate of the patients treated with the EPC capture
evice was 9.4%, 15.6% and 16.6% at 6,12 and 24 months respec-
ively (see Fig. 2 for Kaplan–Meier curve). Target vessel failure
clinically driven TVR, recurrent infarction or cardiac death that
annot be attributed to a vessel other than the target vessel) was
.3% at 6 month FU and 14.6% at 12 and 24 month FU (Table 3).
Angiographic FU occurred in 89.9% (86/96 patients; 99 lesions)
t 6months and in 78.1% (75/96 patients; 87 lesions) at 18months.
he mean in-stent luminal diameter (MLD) in the Genous Stent
t 6 months was 1.81±0.68mm (post-procedural in-stent MLD
.57±0.41mm), whereas late luminal loss was 0.76±0.50mm by
CA (Table 4). At 18-month angiographic FU, mean MLD increased
o 1.86±0.68, whereas late luminal loss signiﬁcantly decreased
o 0.67±0.54 (12% reduction as compared to 6 month FU; 10%
eduction using serial matched analysis, P=0.001). There was no
ifference in late luminal loss between diabetics and non diabetics
0.76±0.56mm vs. 0.76±0.50mm).
.3. Circulating EPC levels in patients receiving the Genous Stent
EPC titer was analyzed before initiation of Atorvastatin 80 qd at
creening, at the index procedure (at 2weeks statin treatment) and
t 1 month FU. Blood samples were quantiﬁed in a blinded fashion
n all 100 patients. At screening, 49% of patients were maintained
n some statin therapy at conventional doses. Two weeks follow-
ng conversion to high dose Atorvastatin, relative EPC levels were
ncreased by 5.6-fold ±1.30 to 63.4 EPCs/100l whole blood, as
ompared to baseline values (Fig. 3D), whereas CD34+ circulating
ematopoietic cells remained largely unaffected by statin therapyary artery
with an increase of only 12% (Fig. 3A). These data suggest that
high dose statin therapy facilitates commitment of the CD34/CD45
hematopoietic cell lineage into the committed endothelial (pro-
genitor) cell fate, rather than recruitment of endothelial progenitor
cells and hematopoietic stem cells from the primary niche. EPC lev-
els remained elevated until the 30-day FU after stent implantation.
4. Discussion
The HEALING IIB clinical trial was a multi-centered, open-label,
prospective study to evaluate the safety and efﬁcacy of a stent
bioengineered to capture circulating EPCs to promote stent re-
endothelialization and initiate vascular healing in combination
with optimized statin therapy. Previously, post-hoc stratiﬁcation
of study patients in the HEALING II study suggested that in particu-
lar patientswith lowEPC titers respondedpoorly to the EPC capture
stent technology with a late loss and TLR events equivalent to bare
metal stents [7]. Moreover, several studies have suggested that
cardiovascular risk factors, including hypertension, aging, hyper-
cholesterolemia, and diabetes mellitus, are associated with low
EPC titers and EPC dysfunction [9]. Low EPC titer in the HEALING II
studywas also associatedwith a lack of statin therapy in these CAD
patients (statin use in patients with low vs. normal EPC levels: 41%
vs. 92%) [7]. Indeed, statin therapy has been shown to augment EPC
levels in vivo, and improve EPC survival, clonal capacity and adhe-
sion in in vitro assays by improved eNOS bioavailability, as well
as via activation of the PI3-Akt dependent eNOS pathway [9–11].
Therefore, we hypothesized that combined treatment of high-dose
statin therapy with the EPC capture stent technology may improve
the response of the patient population with low EPC titers, and
the overall response to this pro-healing concept of percutaneous
coronary intervention.
At enrollment, 79% of CAD patients were already maintained
on statin therapy (34% Atorvastatin, 45% other statin therapy).
Within two weeks after initiation of high dose Atorvastatin phar-
macotherapy, relative EPC levels increased by 5.6-fold at the time
of the index procedure and maintained elevated during a 30-
day FU. Despite effective EPC recruitment, treatment of elective
patients with de-novo coronary artery disease with the EPC cap-
ture Genous Stent resulted at 6-month angiographic FU in a late
luminal loss of 0.76±0.50, and a QCA-derived percent volume
obstruction of 34±26% (Table 4). The overall ischemia-driven and
non-ischemia-driven revascularization rate at 6-month FU com-
prised 6.3%, whereas all MACE were 9.4%. These data are not
signiﬁcantly different from the results of the HEALING II study,
although MACE seems somewhat increased in the HEALING IIB
study. This differencemay be explained by the fact that in theHeal-
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ings of antibodies that speciﬁcally capture EPCs and immobilize
these to the strut surface have been shown to accelerate endothe-
lialization of the stent within 24h following stent implantation inig. 2. Kaplan–Meier curve showing the event free survival for major adverse car
-wave myocardial infarction, emergency cardiac surgery and clinically justiﬁed ta
ng II study patients with only one vessel disease were included,
hereas in the HEALING IIB study, patients with multivessel dis-
ase were also included, making them more complex patients and
ore susceptible to MACE. Consequently, the number of study
tents per patient and total stent length was signiﬁcantly higher
n the HEALING IIB study (see Table 2). Remarkably, comparable
ith the HEALING II study, angiographic late loss was signiﬁcantly
educedby0.10mm(bymatched serial analysis,P=0.001) between
and18months. This ﬁnding contrastswithﬁndings inDES treated
atients, where a progression of late loss is generally observed [12].
urthermore, one could speculate whether this regression in late
uminal losswas reﬂected in clinical outcome, asMACEandTLR sta-
ilized between 12 and 24 month FU. The question can therefore
e raised whether the apparent advantage of DES in comparison
ith theEPC capture stent is only a temporal advantage, orwhether
onger-termclinical outcomeswill prove otherwise. To address this
uestion, randomized studies comparingDESand theGenousStent,
ith clinical and angiographic FU after 24 months are required.
.1. Re-endothelialization to inhibit in-stent restenosis formation
The assumption that regrowth of endotheliummay limit neoin-
imal accumulation has raised inconsistent results in pre-clinical
nd clinical studies. In gently denudated rat aortas, smooth mus-
le cell proliferation is not increased subjacent to the areas of
ndothelial loss [13]. In rat carotid arteries, neointimal accumu-
ation after arterial injury is more related to medial injury than
ndothelial loss [14]. In balloon-injured rabbit iliofemoral arteries,
arly restoration of endotheliumbyautologous endothelial seeding
id not decrease neointimal accumulation [15]. Human atheroscle-
otic plaques have been shown to develop under morphologically
ntact endothelium [16], whereas endothelialized human coronary
tents also contained substantial neointimal hyperplasia [17]. Thisvents (MACE). Mace are deﬁned as the incidence of cardiac death, Q-wave or non
sion revascularization.
suggests that the presence of endothelium and a resistance to inti-
mal growth hence is not inextricably linked. In contrast, in a rabbit
arterial balloon injury model, local delivery of VEGF accelerated
stent endothelialization and reduced neointimal hyperplasia at 28
days FU [18].
Various studies have shown that circulating EPCs are up-
regulated following arterial injury and incorporated at the site of
balloon or stent injury to form a new endothelial lining and ini-
tiate the vascular repair response [19]. Also, low circulating EPC
levels or dysfunctional EPCs in CAD patients were associated with
an increased risk of restenosis formation [20]. Stents bearing coat-Fig. 3. Effect of high dose Atorvastatin on circulating CD34+ haematopoietic cells
andEPC levels.HighdoseAtorvastatin leads toamild increase inCD34+haematopoi-
etic cells (A), whereas absolute and relative EPC count weremarkedly increased (B
and D). There was a subsequent increase in EPC/CD34+ haematopoietic stem cell
(HSC).
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rabbit aortic and porcine iliofemoral and coronary arteries (RGD
coating [21], anti-CD105 coating [Active Endothelial Cell Capture
by Stents Coated with Antibody against CD105, Song et al. TCT Asia
Paciﬁc 2009], and anti-CD34 coating).
However, the role of circulating EPCs on progression of
atherosclerosis and neointimal hyperplasia is poorly under-
stood and various lines of research have yielded conﬂicting
results. Whereas Rausher and co-workers demonstrated that bone
marrow-derived mononuclear cells attenuated the atherosclerotic
burden in ApoE-deﬁcient mice, others have shown that in the
ApoE-deﬁcient mice intravenous infusion of bone marrow derived
mononuclear cellspromotedatherosclerosis formationand in some
studies was also associated with a more vulnerable composition of
the atherosclerotic lesions with enhanced vascularization, larger
lipid cores, thinner ﬁbrous caps and higher numbers of inﬁltrating
CD3 cells [22]. Also, the effect of CD34+ circulating endothelial and
smooth muscle progenitor cells on post-injury neointimal hyper-
plasia is poorly understood. Whereas some studies indicated a
beneﬁt on in-stent neointimal hyperplasia in stented pig arte-
rial segments explanted at different time points [23], others have
failed to demonstrate a beneﬁt in in-stent neo-intimal hyperpla-
sia in porcine coronary arteries, despite a beneﬁt on EPC capture
and accelerated endothelialization (EPC capture in stented porcine
coronary arteries increases endothelialization, but does not affect
intimal thickening, HM van Beusekom et al., accepted in CCI, 2011).
Also, accelerated coverage of PTFE prosthetic vascular in a porcine
AV shunt graft model failed to prevent neointimal hyperplasia at
the venous anastomosis, and actually, stimulated cellular prolif-
eration led to prominent neointima formation [24]. The current
study suggests that despite stimulation of EPC titer in all elective
CAD patients, accelerated coverage of the EPC capture stent did not
seem to impede restenosis formation and clinicalMACE at 6month
FU and questions the paradigm that early re-endothelialization is a
prerequisite for appropriate attenuation of neointimal hyperplasia.
Even though we were unable to ﬁnd an early effect on restenosis,
there was a signiﬁcant long term effect in terms of a reduction in
late luminal loss between 6 and 18 months. This regression was
accompanied by a stabilization of MACE and TLR rates between 12
and 24 months FU.
4.2. Re-endothelialization to inhibit in-stent thrombosis
Alternatively, accelerated re-endothelialization by an EPC cap-
ture stent technology may provide a non-thrombogenic coating
of the exposed stent struts, thereby reducing the risk of in-
stent thrombosis and potentially decreasing or eliminating the
need for anti-thrombotic therapy. Recently, we showed in an ex
vivo human and baboon shunt model that in-stent thrombosis
is decreased in the Genous Stent when compared to BMS [25].
Together with a decrease in mural thrombi, we showed a sig-
niﬁcant decrease in expression of tissue factor pathway inhibitor
(TFPI) and plasminogen activator inhibitor-1 (PAI-1), markers of
thrombosis and coagulation, in the Genous Stent compared to BMS.
On the contrary, some animal studies of arterial injury have pre-
viously suggested that thrombogenicity following arterial injury
decreases in the absence of endothelialization. For instance, in
balloon-injured rabbit aortas platelet deposition occurred within
minutes, but did not increase over the subsequent 24h [26].
Despite the absence of endothelialization, over the course of a
week, the number of vessel-adhered platelets actually decreased,
indicating that thrombogenicity decrease preceded endothelial
regrowth. Moreover, exposed smooth muscle cells in balloon-
injured rat carotid arteries were able to maintain a relatively
non-thrombogenic surface [27]. Local delivery of VEGF in stented
iliac arteries of non-atherosclerotic rabbits resulted in a near com-
plete re-endothelialization by day 7 following stent implantation
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Table 4
Principal effectiveness and safety (results n=96 patients, n=110 lesions).
Effectiveness measures Post procedure 6 months FU 18 months FU
Angiographic success 97.3% (107/110)
Procedural success 93.0% (89/96)
In-stent binary restenosis rate 23.0% (23/99)
RVD 2.95±0.50 (n=110) 2.79±0.61 (n=96) 2.72±0.60 (n=84)
MLD 2.57±0.41 (n=110) 1.81±0.68 (n=99) 1.86±0.68 (n=87)
% DS in-stent 12.73±6.20 (n=110) 35.2±18.74 (n=99) 31.75±19.96 (n=87)
Stent thrombosis 3.1% (3/96) 3.1% (3/96)
Late loss in-stent (mm) 0.76±0.50 (n=99) 0.67±0.54 (n=86)
Acute gain in-stent (mm) 1.42±0.38 (n=107)
In-stent malapposition 0.0% (0/62)
QCA in-stent volume obstruction 32.68±25.2 (n=96) 22.5±28.33 (n=84)
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eferencevesseldiameter (mm);MLD:minimal luminaldiameter (mm);%DS:percen
eviation
ersus placebo delivery with an associated reduction of mural
hrombus formation. Even though the strength of the inverse cor-
elation between stent endothelialization and the development of
rganized thrombus was relatively low (r2 = .52), these results sug-
est that next to endothelialization, other factors play an important
ole in thrombus suppression [28].
Recent autopsy andangioscopy studies suggested that following
mplantation of sirolimus eluting stents (SES) andpaclitaxel eluting
tents (PES), reendothelialization and arterial healing was incom-
lete for up to 6–12 months, therefore rendering the vessel more
rone to late in-stent thrombosis [29]. More extensive endothelial
ysfunction and impeded arterial repair following implantation of
ES/PES in remote vascular segments have been suggested by a
ersistent aberrant coronary vasomotor response to exercise and
cetylcholine stimulation of the vascular segments adjacent to the
mplanted stent. The secondary endpoints of theHEALING IIB study
herefore included in-stent thrombosis at 30 days and incidence
f MACE at 6-month FU. Three Patients suffered from a deﬁnite
n-stent thrombosis at day 1, 9 and 181 days following the index
rocedure (by ARC deﬁnitions). The overall 3% incidence of deﬁnite
n-stent thrombosis does not suggest an anti-thrombotic capacity
f the EPC capture stent technology in the current study; however,
ll three events had documented signiﬁcant procedural compli-
ations, which might have facilitated the in-stent thrombosis. For
xample, in theHEALING II study 0% stent thrombosiswas reported
nd in the e-HEALING clinical registry of a real-world population
n=4939) treatedwith theGenous Stent, the 12month deﬁnite and
robable stent thrombosis rate was 1.1% [30]. Moreover, it should
enoted that the current studywas largelyunderpowered toobtain
reliable estimate of the stent thrombosis rate with the Genous
tent. The stent thrombosis rate reported in the e-HEALING reg-
stry seems to conﬁrm the favorable real world results with the
enous Stent, even in the absence of prolonged dual anti-platelet
herapy.
A limitation of the study is the low compliance to 18 month
ngiographic follow up (78.1%, 75/96), which may have resulted in
oss-to-follow up bias and underestimation of the stent thrombosis
ate or late luminal loss.
In conclusion, in the HEALING IIB study, 100 elective patients
ith de novo coronary artery lesions received a Genous Stent in
onjunctionwithHmG-CoA-reductase inhibitors (statins) to stimu-
ate EPC recruitment. Althoughhigh dose statin therapy adequately
nhanced EPC titers at the index procedure, the EPC capture stent
echnology did not sufﬁciently impede clinical restenosis rates
nd late luminal loss at 6 month angiographic FU. However, a
igniﬁcant reduction in late luminal loss was observed between
and 18 month angiographic FU which was accompanied by a
tabilization of MACE and TLR rates between 12 and 24 months
U.
[Q-wave, emergent CABG or clinically driven TLR as determined by the CEC; RVD:
eter stenosis;numbersare% (counts/availableﬁeld sample size)ormean± standard
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